actively trading these days
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Translations of Chinese to English always suck.
ST?? Ah, StockTwits? Sure.
I got a response from my colleague in China. I asked him if he could find anything about Five Grain Treasures Spirit. However, I am not at all sure this is the company that Henry acquired. I have written this company to see if they have a relationship with PHI. Here is his email to me:
Dear Thomas,
I wonder the company metioned was Wuliangye. If the Wuliangye was translated word by word, then it will be the Five Grain Treasures Spirit.
Wuliangye was one leading producer of Chinese spirit, and its sales reached twenty billions of US dollars per year. Following is its website.
https://www.wuliangye.com.cn/zh/main/
However, I cannot find the website of this company in English. If you want to get more about the company, you can ask me directly.
Best
PRs cost money, and many are using Twitter these days in its place.
I've sent emails to several of my colleagues in China re Five Grains. Let's see what they find out.
Been hearing that for two years.
They may supply to the largest distiller in the world, but maybe they only sell them 10 gallons of product per year. How MUCH they supply is what counts, and I see no estimate of that yet.
Good email.
OK. We are now past Labor Day. Time to light this candle.
I agree, but volume is habitually low, so there is little movement at all. I am seeing this with every stock I own. Summer after summer after summer.
It's just August.
Maybe that is his reason, but most stocks like this never file. Filing has to make this shell more valuable to a potential suitor.
But he keeps up with the filings, which is very encouraging for this kind of stock.
Somebody is buying up this sucker.
And back to the 50s we go.
It did seem like a small sample size.
This new base at about .025 works for me as we prepare to move to the .05 range.
Link to news, please.
IMO, some new investors jumped in big, and then some of the existing holders sold at those elevated prices. Just a change of hands.
Something is happening this am, but I see no news yet. Huge pm volume.
Where do you see that?
AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million
Boca Raton, FL – July 22, 2021 -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9,090,910 shares of common stock of the Company, at a price to the public of $0.55 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 27, 2021, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
The Company has granted to the underwriter a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to AzurRx, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter’s option to purchase additional common stock, are expected to be approximately $5.0 million. The Company intends to use the net proceeds from this offering for milestone payments due under our license agreements and for other general corporate purposes, which may include product manufacturing, clinical development, acquisitions or investments in complementary businesses, products or technologies, and/or increases in working capital.
The shares of common stock are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-256476) previously filed with the Securities and Exchange Commission (the “SEC”) on May 26, 2021, and declared effective by the SEC on June 2, 2021. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to, and describing the terms of, the offering have been filed with the SEC and are available on the SEC’s website at http://www.sec.gov. A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and, upon filing, may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs in 2021 using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-1022 for COVID-19 gastrointestinal infections, and FW-420 for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California. For more information, visit www.azurrx.com.
Well, this sucks.
Volume has really dropped off on this one the past few days.
Wow. Pre-sold!!
IMO, closing even or only slightly green with this volume is very bullish. New level is being established every day.
I really doubt that, but hope you are correct.
Barely at all. It is not a crash, just another of many daily declines of 500 points.
Expecting a good week here. Close of .035 by Friday, IMO.
I really think it will, and I'm not pumping.
A lot more communication from Bill these days. Good stuff.
Looks like I might get my wish. Close above .025 today!
This trading is looking and feeling very nice, especially for July. September should be a lot of fun.
Was hoping we would close above .025 by tomorrow.
Looks like someone just bought 500K shares at the ask.
I'm finally in the green with this thing.
I say we permanently break through .02 today.
Does anyone have any revenue projections for these crops given the number of plants being put in the ground, number of harvests per year, etc.?
Trading up very well today. Lots to look forward to.
I'm ok with the trading currently. Almost nothing exciting ever happens in July or August with these stocks. We are holding with good volume.